Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition


Nes Ziona, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive top-line results of an investigator-initiated clinical trial of AllocetraTM in COVID-19 patients in severe/critical condition.

Original post:
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition

Related Posts